Patents Assigned to ADAPTIVE BIOTECHNOLOGIES CORPORATION
  • Patent number: 10323276
    Abstract: Methods are provided for producing monoclonal antibody candidates using adaptive immunity profiling. In some aspects, the method provides for the use of massively parallel signature sequencing.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: June 18, 2019
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventor: Steven R. Wiley
  • Patent number: 9394567
    Abstract: The invention is directed to methods for detecting and quantifying nucleic acid contamination in a tissue sample of an individual containing T cells and/or B cells, which is used for generating a sequence-based clonotype profile. In one aspect, the invention is implemented by measuring the presence and/or level of an endogenous or exogenous nucleic acid tag by which nucleic acid from an intended individual can be distinguished from that of unintended individuals. Endogenous tags include genetic identity markers, such as short tandem repeats, rare clonotypes or the like, and exogenous tags include sequence tags employed to determine clonotype sequences from sequence reads.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: July 19, 2016
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Thomas Asbury, Victoria Carlton, Malek Faham, Stephen C. Macevicz, Martin Moorhead, Thomas Willis, Jianbiao Zheng
  • Patent number: 9279159
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 8, 2016
    Assignees: ADAPTIVE BIOTECHNOLOGIES CORPORATION, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Harlan S. Robins, Robert J. Livingston, Jason H. Bielas
  • Patent number: 9181591
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: November 10, 2015
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Harlan S. Robins, Robert J. Livingston
  • Patent number: 9181590
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: November 10, 2015
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Harlan S. Robins, Robert J. Livingston
  • Publication number: 20130288237
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 31, 2013
    Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: ADAPTIVE BIOTECHNOLOGIES CORPORATION, FRED HUTCHINSON CANCER RESEARCH CEN
  • Publication number: 20130253842
    Abstract: Methods are described for diagnosis of a lymphoid hematological malignancy in a subject prior to treatment, and for detecting minimal residual disease (MRD) in the subject after treatment for the malignancy, by high throughput quantitative sequencing (HTS) of multiple unique adaptive immune receptor (TCR or Ig) encoding DNA molecules that have been amplified from DNA isolated from blood samples or other lymphoid cell-containing samples. Amplification employs oligonucleotide primer sets designed to amplify CDR3-encoding sequences within substantially all possible human VDJ or VJ combinations. Disease-characteristic adaptive immune receptor clonotypes occur, prior to treatment, at a relative frequency of at least 15-30% of rearranged receptor CDR3-encoding gene regions. Following treatment, persistence of at least one such clonotype at a detectable frequency of at least 10?6 or at least 10?5 receptor CDR3-encoding regions indicates MRD.
    Type: Application
    Filed: December 7, 2012
    Publication date: September 26, 2013
    Applicant: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Anna M. Sherwood, Harlan S. Robins